HI-PRO: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Don't Just Read the AbstractShow Notes
On this episode, Pip and Rich discuss Piazza et al. Apixaban for Extended Treatment of Provoked Venous Thromboembolism, published in the New England Journal of Medicine in August 2025. This trial randomised 600 patients with VTE provoked by a transient risk factor but who also had at least one enduring risk factor, after completing 3 months of anticoagulation, to receive either apixaban 2.5 mg twice daily or placebo for 12 months. Extended apixaban reduced recurrent VTE from 10.0% to 1.3% (HR 0.13, 95% CI 0.04–0.36) with very low rates of major bleeding, though clinically relevant non-major bleeding was more frequent.
The caveat to these findings is the definition of "provoked" used in the trial, which is wide-ranging. This is an insightful discussion and is highly relevant to clinical practice. Hosted on Acast. See acast.com/privacy for more information.
More from Don't Just Read the Abstract
On this episode, Pip and Rich talk to Dr Noma Tshuma, a haematology registrar and Clinical Research Fellow + PhD student at the University of Cambridge. During her time as an AI fellow at University College London Hospitals, Noma developed the Data Clinic, a structure through which clinical research using real world evidence could be performed using technology with a fraction of the effort needed for manual data extraction. We discuss the practicalities of the project as well as speculating about the future. A must listen for anyone interested clinical evidence. Hosted on Acast. See acast.com/privacy for more information.
On this episode, Pip and Rich discuss HI-PEITHO, a randomised controlled trial of catheter-directed fibrinolysis in patients presenting with intermediate risk PE. This was an industry-sponsored trial. Patients could be included if they had a ratio of RV:LV end diastolic diameter of ≥1.0 and an elevated troponin level + at least two of SBP ≤110 mm Hg, HR ≥100 bpm, or a respiratory rate of >20 breaths per minute.
In this episode, Pip and Rich discuss the C-TRACT trial: Vedantham et al. Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial. 2026 N Engl J Med 2026;394:2293-2304
On this episode, Pip and Rich discuss the FRONTIER2, the phase 3 trial of Mim8 (denecimig) for prophylaxis in haemophilia A with or without inhibitors. They review the study design, efficacy and safety results, and consider where Mim8 may fit into the rapidly evolving haemophilia treatment landscape. They also explore the key unanswered question: does Mim8 offer any meaningful clinical advantage over emicizumab, or is its main benefit greater convenience through fixed-volume administration? Hosted on Acast. See acast.com/privacy for more information.
On this episode, Pip and Rich chat to Consultant Haematologist, Dr Kate Musgrave and Thrombosis Nurse Specialist, Vicky Marr about how they developed and implemented a natural language processing model that identifies cases of hospital acquired thrombosis. Implementing this strategy in their hospital in Newcastle-Upon-Tyne has led to saving thousands of hours of manually trawling radiology reports - enabling them to focus on what matters - interacting with patients. The tool is now available for implementation across the NHS. This is a must-listen for anyone wanting to improve efficiency in their hospital.